TVTX: Travere Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,598.82
Enterprise Value ($M) 1,940.97
Book Value ($M) -30.45
Book Value / Share -0.35
Price / Book -52.50
NCAV ($M) -210.12
NCAV / Share -2.41
Price / NCAV -7.61

Profitability (mra)
Return on Invested Capital (ROIC) -0.94
Return on Assets (ROA) -0.45
Return on Equity (ROE) -1.75

Liquidity (mrq)
Quick Ratio 1.68
Current Ratio 1.71

Balance Sheet (mrq) ($M)
Current Assets 324.74
Assets 504.41
Liabilities 534.86
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G/A Deep Track Capital, LP 0.70 -92.93
11-14 13G Woodline Partners LP 5.70
11-14 13G/A Armistice Capital, Llc 10.00 3.58
11-12 13G/A Vanguard Group Inc 9.02 0.00
11-08 13G/A Morgan Stanley 1.70 -68.22
10-18 13G/A State Street Corp 3.60 -48.87
05-01 13G Rock Springs Capital Management LP 5.79
02-14 13G/A Macquarie Group Ltd 6.31 33.47
02-12 13G/A Janus Henderson Group Plc 0.00 -99.37
02-07 13G/A Adage Capital Partners Gp, L.l.c. 0.67 -88.69
01-24 13G/A BlackRock, Inc. 10.60 3.74

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-02-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-21 807,946 1,683,336 48.00
2025-01-17 228,921 574,488 39.85
2025-01-16 216,924 624,370 34.74

(click for more detail)

Similar Companies
TRDA – Entrada Therapeutics, Inc. TRVI – Trevi Therapeutics, Inc.
TSBX – Turnstone Biologics Corp. URGN – UroGen Pharma Ltd.
VCEL – Vericel Corporation


Financial data and stock pages provided by
Fintel.io